Transdermal opioids for cancer pain

Health and Quality of Life Outcomes

Volumn 4, Issue , 2006, Pages

  Skaer, Tracy L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALFENTANIL; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIHISTAMINIC AGENT; BUPRENORPHINE; CODEINE; FENTANYL; HYDROMORPHONE; HYPNOTIC AGENT; MORPHINE; MUSCLE RELAXANT AGENT; OPIATE DERIVATIVE; OPIATE RECEPTOR; OXYCODONE; PARACETAMOL; PETHIDINE; PHENOTHIAZINE DERIVATIVE; REMIFENTANIL; SEDATIVE AGENT; SUFENTANIL; TRANQUILIZER;

ADVANCED CANCER; ALGORITHM; ANXIETY DISORDER; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAPULE; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; AUSTRALIA; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TOLERABILITY; EUROPE; HEALTH CARE DELIVERY; HUMAN; HYPOTENSION; HYPOVENTILATION; NAUSEA; NONHUMAN; PHYSICIAN; PRESCRIPTION; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SHIVERING; SKIN IRRITATION; SOMNOLENCE; UNITED KINGDOM; UNITED STATES; VOMITING; WITHDRAWAL SYNDROME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ALGORITHMS; ANALGESICS, OPIOID; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FENTANYL; HUMANS; NEOPLASMS; PAIN, INTRACTABLE; PALLIATIVE CARE; TITRIMETRY;

EID: 33746784667     PISSN: 14777525     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-4-24     Document Type: Review

References (48)

1. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994, 330:592-596.
2. Simmonds MA: Pharmacotherapeutic management of cancer pain: Current practice. Semin Oncol 1997, 24(5 Suppl 16):S161-6.
3. Grond S, Zech D, Diefenbach C, Bischoff A: Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994, 9:372-382.
4. Zhukovsky DS, Gorowski E, Hausdorff J, Napolitano B, Lesser M: Unmet analgesic needs in cancer patients. J Pain Symptom Manage 1995, 10:113-119.
5. Reddick BK, Nanda JP, Campbell L, Ryman DG, Gaston-Johansson F: Examining the influence of coping with pain on depression, anxiety, and fatigue among women with breast cancer. J Psychosoc Onco 2005, 23:137-157.
6. Mystakidou K, Tsilika E, Parpa E, Katsonda E, Galanos A, Vlahos L: Assessment of anxiety and depression in advanced cancer patients and their relationship with quality of life. Qual Life Res 2005, 14:1825-1833.
7. Bucher JA, Trostle GB, Moore M: Family reports of cancer pain, pain relief, and prescription access. Cancer Pract 1999, 7:71-77.
8. Hanks GW: Cancer pain and the importance of its control. Anticancer Drugs 1995, 6:14-17.
9. World Health Organization: Cancer pain relief: with a guide to opioid availability 2nd edition. Geneva: WHO; 1996.
10. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA: Validation of World Health Organization guidelines for cancer pain relief: A 10-year prospective study. Pain. 1995, 63:65-76.
11. Schug SA, Merry AF, Acland RH: Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs 1991, 42:228-239.
12. Zenz M, Strumpt M, Tryba M: Long-term oral opioid therapy in patienss with chronic nonmalignant pain. J Pain Symptom Manage 1992, 7:69-77.
13. Portenoy RK: Opioid therapy for chronic nonmalignant pain: A review of the critical issues. J Pain Symptom Manage 1996, 11:203-217.
14. Arner S, Meyerson BA: Lack of analgesic effect of opinoids on neuropathic and idiopathic forms of pain. Pain 1988, 33:11-23.
15. Foley KM: The treatment of cancer pain. N Engl J Med 1985, 313:84-95.
16. Cherny NI, Portenoy RK: The management of cancer pain. CA Cancer J Clin 1994, 44(5):262-303.
17. Levy MH: Pharmacologic treatment of cancer pain. N Engl J Med 1996, 335:1124-1132.
18. Lawlor P, Turner K, Hanson J, Bruera E: Dose ratio between morphine and hydromorhone in patients with cancer pain: A retrospective study. Pain 1997, 72:79-85.
19. Lawlor PG, Turner KS, Hanson J, Bruera ED: Dose ratio between morphine and methadone in patients with cancer pain. Cancer 1998, 820:1167-1173. 1(mcg/hr)
20. Muijers RBR, Wagstaff AJ: Transdermal Fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001, 61:2289-2307.
21. Janssen Pharmaceutica: Duragesic (Fentanyl transdermal system) full prescribing information. U.S 2001.
22. Kornick CA, Santiago-Palma J, Moryl N, Payne R, Obbens EA: Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003, 26:951-973.
23. Donner B, Zenz M, Tryba M, Strumpf M: Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain 1996, 64:527-534.
24. Higgs C, Vella-Brincat J: Withdrawal with transdermal fentanyl. J pain Symptom Manage 1995, 10:4-5.
25. Zenz M, Donner B, Strumpf M: Withdrawal symptoms during therapy with transdermal fentanyl (Fentanyl TTS). J Pain Symptom Manage 1994, 9:54-55.
26. Radbruch L, Elsner F: Clinical experience with transclermal fentanyl for the treatment of cancer pain in Germany. Keio J Med 2004, 53:23-29.
27. Mystakidou K, Parpa E, Tsilika E, Katsouda E, Kouloulias V, Kouvaris J, Georgaki S, Vlahos L: Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. J Pain 2004, 5:119-132.
28. Breitbart W, Chandler S, Eagel H, Ellison N, Enck RE, Lefkovvitz M, Payne R: An alternative algorithm for dosing of transdermal fentanyl for cancer-related pain. Oncology 2000, 14:695-705.
29. Cleary JF: Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol 1997, 24(5 Suppl 16):S16-13-19.
30. Payne R, Chandler S, Einhaus M: Guidelines for the clinical use of transdermal fentanyl. Anti-Cancer Drugs 1995, 6:50-53.
31. The TTS Fentanyl Multicentre Study Group: Transdermal fentanyl in cancer pain. J Drug Dev 1994, 6:93-97.
32. Southam MA: Transdermal fentanyl therapy. System design, pharmacokinetics and efficacy. Anticancer Drugs 1995, 6(6 Suppl 3):29-34.
33. Portenoy RK, Southam M, Gupta SK: Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics and efficacy. Anesthesiology 1993, 78:36-43.
34. Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manag 1996, 13:254-261.
35. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K: Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients With cancer and chronic non-cancer pain. Curr Med Res Opin 2004, 20:1419-1428.
36. Wong JO, Chiu GL, Tsao CJ, Chang CL: Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997, 35:25-32.
37. Kongsgaard UE, Poulain P: Transdermall fentanyl for pain control in adults with chronic cancer pain. Eur J Pain 1998, 2:53-62.
38. Evans HC, Easthope SE: Transdermal buprenorphine. Drugs 2003, 63:1999-2010.
39. Johnson RE, Fudala PJ, Payne R. Buprenorphine: Considerations for Pain Management. J Pain Symptom Manage 2005, 29:297-326.
40. Bohme K: Burprenorphine in a transdermal therapeutic system - A new option. Clin Rheumatol 2002, 21:S13-116.
41. Budd K: Buprenorphine and the transdermal system: The ideal match in pain management. Int J Clin Pract Suppl 2003, 133:9-14.
42. Radbruch L, Vielvoye-Kerkmeer A: Buprenorphine TDS: The clinical development, rationale and results. Int J Clin Pract Suppl 2003, 133:15-18.
43. Radbruch L: Suprenorphine TDS: Use in daily practice, benefits for patients. Int J Clin Pract Suppl 2003, 133:19-24.
44. Sittl R: Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother 2005, 5:315-323.
45. Sittl R, Griessinger N, Likar R: Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003, 25:150-168.
46. Bohme K, Kikar R: Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain: a randomized, double-blind, placebo-controlled-study. Pain Clinic 2003, 15:193-202.
47. Sorge J, Reinhard S: Transdermall buprenorphine in the treatment of chronic pain: results of a phase III, mulitcenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004, 26:1808-1820.
48. Muriel C, Failde I, Mico JA, Neira M, Sanchez-Magro I: Effectiveness and tolerability of the burprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther 2005, 27:451-462.